Mitsubishi UFJ Asset Management Co. Ltd. Raises Holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Mitsubishi UFJ Asset Management Co. Ltd. boosted its stake in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 9.1% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 7,483 shares of the company’s stock after acquiring an additional 627 shares during the quarter. Mitsubishi UFJ Asset Management Co. Ltd.’s holdings in IDEAYA Biosciences were worth $123,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently bought and sold shares of the stock. Deutsche Bank AG boosted its holdings in IDEAYA Biosciences by 25.3% during the 1st quarter. Deutsche Bank AG now owns 467,461 shares of the company’s stock valued at $7,657,000 after acquiring an additional 94,482 shares during the period. Vanguard Group Inc. boosted its holdings in IDEAYA Biosciences by 0.3% during the 1st quarter. Vanguard Group Inc. now owns 5,092,619 shares of the company’s stock valued at $83,417,000 after acquiring an additional 14,535 shares during the period. PNC Financial Services Group Inc. boosted its holdings in IDEAYA Biosciences by 180.2% during the 1st quarter. PNC Financial Services Group Inc. now owns 2,404 shares of the company’s stock valued at $39,000 after acquiring an additional 1,546 shares during the period. XTX Topco Ltd lifted its holdings in IDEAYA Biosciences by 138.3% in the 1st quarter. XTX Topco Ltd now owns 30,215 shares of the company’s stock worth $495,000 after buying an additional 17,536 shares during the period. Finally, Fiera Capital Corp lifted its holdings in IDEAYA Biosciences by 2.1% in the 1st quarter. Fiera Capital Corp now owns 1,209,865 shares of the company’s stock worth $19,818,000 after buying an additional 25,398 shares during the period. 98.29% of the stock is currently owned by hedge funds and other institutional investors.

IDEAYA Biosciences Stock Performance

Shares of NASDAQ:IDYA opened at $24.37 on Friday. IDEAYA Biosciences, Inc. has a 52-week low of $13.45 and a 52-week high of $40.74. The firm has a market capitalization of $2.14 billion, a P/E ratio of -6.43 and a beta of 0.09. The stock has a 50 day moving average price of $22.68 and a 200-day moving average price of $20.39.

IDEAYA Biosciences (NASDAQ:IDYA) last posted its quarterly earnings data on Tuesday, August 5th. The company reported ($0.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.03). The company had revenue of $6.00 million during the quarter, compared to the consensus estimate of $3.48 million. During the same period in the previous year, the business posted ($0.68) earnings per share. The firm’s quarterly revenue was up NaN% compared to the same quarter last year. On average, equities analysts forecast that IDEAYA Biosciences, Inc. will post -3.07 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the company. JPMorgan Chase & Co. increased their price objective on IDEAYA Biosciences from $66.00 to $72.00 and gave the stock an “overweight” rating in a report on Monday, July 28th. The Goldman Sachs Group upgraded IDEAYA Biosciences to a “hold” rating and set a $25.00 price objective for the company in a report on Thursday, July 10th. Wells Fargo & Company assumed coverage on IDEAYA Biosciences in a report on Thursday, June 26th. They issued an “overweight” rating and a $44.00 price objective for the company. Royal Bank Of Canada upgraded IDEAYA Biosciences from an “outperform” rating to a “moderate buy” rating and dropped their price objective for the stock from $57.00 to $30.00 in a report on Wednesday, July 9th. Finally, TD Cowen initiated coverage on IDEAYA Biosciences in a report on Tuesday, July 22nd. They issued a “buy” rating for the company. Three equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $48.09.

IDEAYA Biosciences Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.